Date: 2022-04-06

Type of information: Plant acquisition

Compound: biologics development and manufacturing facility currently under construction near Oxford (UK)

Company: Catalent (USA)

Therapeutic area: Technology - Services

Type agreement: plant acquisition

Action mechanism:


Details: • On April 6, 2022, Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities,announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction near Oxford, U.K. Catalent plans to invest up to $160 million (£120 million) to complete the building of the facility and equip it with state-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins, and other advanced modalities. It is expected that the new facility will employ more than 400 people and support public and private organizations seeking to develop and manufacture biotherapeutics. “Our priority is to complete construction as soon as possible to be able to commence customer programs in 2022, commented Mike Riley, President of Catalent Biotherapeutics. We will then integrate its capabilities within our existing network of biologics facilities across Europe to offer a flexible range of manufacturing, technology, and development solutions for the pipeline of thousands of development programs currently underway.” The new facility is located to the south of Oxford at the world-renowned Harwell Science and Innovation Campus, a leading site in the U.K. for science and technology research breakthroughs and home to more than 40 life science companies. Last year, the VMIC has been granted an additional £47.6 million to support the expansion and acceleration of the programme. The funding has supported work already underway to expand the capacity twenty-fold so that the UK has a highly specialist manufacturing centre that, in a pandemic situation, can make up to 70 million doses within a 6 month period and to accelerate the timeline for VMIC to be operationally ready so it can support the national response to (coronavirus) COVID-19. VMIC has been granted almost £215 million of government funding in total.  

Financial terms:

Latest news:

Is general: Yes